It leaves with very few viable treatment options.

Advanced NSCLC patients with PS 2 have a poor prognosis and often less aggressive chemotherapy due to poor or no tolerance, it leaves with very few viable treatment options. The subset analysis of patients with PS 2 had a median survival time of 4 months and one – year survival rate of 15.

.. Are the data of 21,064 patients, the 1 doses were sent gefitinib1. ‘andomized to treatment if they had received and failed more than one course of standard chemotherapy or radiotherapy for their NSCLC? 1-year survival rate was 29.9 percent (95 percent CI, 8 to 31, the median survival time was 5.3 months (CI, 3 percent of patients a severe a serious drug-related adverse event and broke the 1.1 percent due to a serious due to a serious drug-related adverse event.

Judith Ochs MD, Senior Director clinical Research, lead author of the study at AstraZeneca commented: the results presented today are consistent with the clinical benefit of gefitinib randomized, double-blind Phase II trials ,, which means that about 4 of patients were alive one year after the the start of treatment were reported.Donor card out of ten Europeans Favour Organ Donor Card – euros barometer reveal.

Among Member States which the EU since 2004 is acceded, the use of organ donation cards extremely limited. , one of their organs after death to donate. Only 42 percent of respondents who nor ever this type of discussion would be donate an organ, and the proportion of people who would not and do not know has click to this group . Public support for the idea of of donation was highest in Sweden , Island of Malta and Finland and the lowest in Romania , Latvia and Austria .